Abstract
Visceral leishmaniasis is a deadly endemic disease. Unresponsiveness to the only available oral drug miltefosine poses a big challenge for the chemotherapy of the disease. We report a novel molecule, PS-203 {4-(4,4,8-trimethyl-7-oxo-3-oxabicyclo[3.3.1]non-2-yl)-benzoic acid methyl ester}, as effective against a miltefosine-unresponsive strain of the parasite. Further, combinations of PS-203 with miltefosine were also evaluated and showed promising results against a miltefosine-unresponsive strain.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiprotozoal Agents / chemical synthesis
-
Antiprotozoal Agents / pharmacology*
-
Benzoates / chemical synthesis
-
Benzoates / pharmacology*
-
Bridged Bicyclo Compounds, Heterocyclic / chemical synthesis
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
-
Cell Line
-
Cell Survival / drug effects
-
Dose-Response Relationship, Drug
-
Drug Resistance / drug effects*
-
Drug Synergism
-
Humans
-
Leishmania donovani / drug effects*
-
Leishmania donovani / growth & development
-
Macrophages / drug effects
-
Macrophages / parasitology
-
Parasitic Sensitivity Tests
-
Phosphorylcholine / analogs & derivatives
-
Phosphorylcholine / pharmacology
Substances
-
4-(4,4,8-trimethyl-7-oxo-3-oxabicyclo(3.3.1)non-2-yl)benzoic acid methyl ester
-
Antiprotozoal Agents
-
Benzoates
-
Bridged Bicyclo Compounds, Heterocyclic
-
Phosphorylcholine
-
miltefosine